🟢 Outlook Therapeutics is trading 11% up today as executive incentives are tied to ONS-5010 FDA approval

Outlook Therapeutics is trading 11% up at $1.47 after the company approved new executive stock option grants and performance-based cash bonuses tied specifically to FDA approval of its lead drug candidate ONS-5010.

• The new compensation structure aligns management incentives directly with the regulatory success of ONS-5010, signaling internal confidence in the FDA outcome.
• Investor attention is focused on this strategic alignment, helping the stock outperform broader market indices which are currently seeing only modest moves.